Photocure ASA - Invitation to a presentation of the 2nd quarter report 2011
Invitation to a presentation of the 2nd quarter report 2011
Photocure ASA will present its second quarter 2011 report on Thursday August 18, 2011 at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway. The presentation will begin at 11.30 (CET). Representatives from the company will be Kjetil Hestdal, President & CEO and Christian Fekete, CFO.
The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation on: http://webtv.hegnar.no/webcast.php?id=22184
Lunch is served from 11:00. The presentation is scheduled to conclude at 12:15.
Please register your attendance at Photocure ASA by Wednesday August 17, 2011 at 15:00.
Contact person: Grete Faye-Schjøll (e-mail: firstname.lastname@example.org / phone +47 22 06 22 10 / fax +47 22 06 22 18).
Christian Fekete, CFO
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocures commercial activities includes own marketing and sales in selected markets as well as out-licensing to leading pharmaceutical companies on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU and in the US. In addition, the company markets Allumera ®, a photodynamic cosmetic in the US. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.
Photocure®, Hexvix®, Cevira® and Allumera® are registered trademarks of Photocure ASA.
For more information about Photocure, visit our website at www.photocure.com